Page 90«..1020..89909192..100110..»

Category Archives: Global News Feed

Biolog-id and Genesis Growth Tech Acquisition Corp. Announce Execution of Business Combination Agreement for Proposed Merger to Create Publicly Listed…

Posted: September 8, 2022 at 2:03 am

Anticipated Cash Resources to be used to Advance Biolog-id Value Chain Optimization Platform for Blood Products and other Biologics Anticipated Cash Resources to be used to Advance Biolog-id Value Chain Optimization Platform for Blood Products and other Biologics

Read more:
Biolog-id and Genesis Growth Tech Acquisition Corp. Announce Execution of Business Combination Agreement for Proposed Merger to Create Publicly Listed...

Posted in Global News Feed | Comments Off on Biolog-id and Genesis Growth Tech Acquisition Corp. Announce Execution of Business Combination Agreement for Proposed Merger to Create Publicly Listed…

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022…

Posted: September 8, 2022 at 2:03 am

— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) —

Go here to see the original:
HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022...

Posted in Global News Feed | Comments Off on HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022…

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

Posted: September 8, 2022 at 2:03 am

SAINT-HERBLAIN, France and CAMBRIDGE, Mass. (September 8, 2022) – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe.

The rest is here:
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

Posted in Global News Feed | Comments Off on Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

Basilea announces sale of preclinical oncology program to Nodus Oncology

Posted: September 8, 2022 at 2:03 am

Basel/Allschwil, Switzerland, September 08, 2022

Original post:
Basilea announces sale of preclinical oncology program to Nodus Oncology

Posted in Global News Feed | Comments Off on Basilea announces sale of preclinical oncology program to Nodus Oncology

Vaccentis strengthens leadership with appointment of Mario Stark as Chief Sales and Marketing Officer

Posted: September 8, 2022 at 2:03 am

Zurich, Switzerland, September 8, 2022 - Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-specific medicines, today announced the appointment of the experienced life science executive Mario Stark as Chief Sales and Marketing Officer, effective immediately.

See original here:
Vaccentis strengthens leadership with appointment of Mario Stark as Chief Sales and Marketing Officer

Posted in Global News Feed | Comments Off on Vaccentis strengthens leadership with appointment of Mario Stark as Chief Sales and Marketing Officer

Pharmazz Inc. announces Indian Central Drugs Standard Control Organization (CDSCO) Clearance of IND to conduct a Phase II clinical trial of…

Posted: August 30, 2022 at 2:32 am

Sovateltide is an endothelin-B receptor agonist that is neuroprotective, neurorestorative, and produces neurovascular remodeling

See the original post:
Pharmazz Inc. announces Indian Central Drugs Standard Control Organization (CDSCO) Clearance of IND to conduct a Phase II clinical trial of...

Posted in Global News Feed | Comments Off on Pharmazz Inc. announces Indian Central Drugs Standard Control Organization (CDSCO) Clearance of IND to conduct a Phase II clinical trial of…

TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with…

Posted: August 30, 2022 at 2:32 am

SAN DIEGO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical trial of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients, including patients who have not received prior therapy.

Read this article:
TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with...

Posted in Global News Feed | Comments Off on TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with…

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Posted: August 30, 2022 at 2:32 am

BOSTON & LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced that members of its management team will participate in the following investor conferences:

Original post:
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Posted in Global News Feed | Comments Off on Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated…

Posted: August 30, 2022 at 2:32 am

DALLAS, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Gradalis Inc. announced a peer-reviewed publication today in the Nature portfolio journal, Communications Medicine, in which several biomarkers were evaluated for their potential to predict survival following Vigil® (Gemogenovatucel-T) treatment. The publication entitled “ENTPD1 as a Predictive Marker of Treatment Response to Gemogenovatucel-T as Maintenance Therapy in Newly Diagnosed Ovarian Cancer,” features results from VITAL, a Phase 2b randomized, double-blind, placebo-controlled trial of Vigil in patients with newly diagnosed ovarian cancer. The analysis indicates that pretreatment expression levels of the ENTPD1 gene may be a significant predictor of overall survival (OS) and recurrence-free survival (RFS) following Vigil therapy. Vigil is a novel, personalized cellular immunotherapy platform that is designed to decloak the full repertoire of a patient’s tumor antigens, reactivate the immune system, and summon key effector cells to deliver a durable clinical response. In VITAL, Vigil showed a positive trend in RFS in the overall population and a significant improvement in RFS and OS in newly diagnosed ovarian cancer patients with BRCAwt and HRP molecular profiles. This finding may allow for a more refined targeting of patients who will benefit from Vigil therapy.

The rest is here:
Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated...

Posted in Global News Feed | Comments Off on Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated…

Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar® Advanced Therapy for Mental Health

Posted: August 30, 2022 at 2:32 am

Latest NeuroStar innovation to simplify the motor threshold determination for clinicians Latest NeuroStar innovation to simplify the motor threshold determination for clinicians

Link:
Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar® Advanced Therapy for Mental Health

Posted in Global News Feed | Comments Off on Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar® Advanced Therapy for Mental Health

Page 90«..1020..89909192..100110..»